Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.
Authors
Julien Edeline
Eugene Marquis Center, Department of Medical Oncology, Rennes, France
Julien Edeline , Philippe Merle , Weijia Fang , Eric Assenat , Hongming Pan , Lorenza Rimassa , Zhiwei Li , Jean-Frederic Blanc , Chia-Jui Yen , Paul J. Ross , Sheng Hu , Tao Zhang , Albert Tran , Guoliang Shao , Mohamed Bouattour , Yajin Chen , John Wu , Bai Li , Sandra Chica-Duque , Zhenggang Ren
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03419897
DOI
10.1200/JCO.2022.40.4_suppl.420
Abstract #
420
Poster Bd #
B7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.
First Author: Julien Edeline
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Outcomes of patients with hepatocellular carcinoma (HCC) treated in the lenvatinib (LEN) and immunotherapy era (2018-2021) compared to the sorafenib (SOR) era (2008-2018).
First Author: Chloe Lim
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of frontline systemic therapy for advanced hepatocellular carcinoma (aHCC): A network meta-analysis of landmark phase III trials.
First Author: Claudia A.M. Fulgenzi
Poster
2021 ASCO Annual Meeting
Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers.
First Author: William Joseph Chapin